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We have performed two separate phase II peptide vaccine
trials in patients with AML/MDS and in patients with
WT1 overexpressing solid tumors with identical vaccine
schedule. Here we concentrate on patients remaining
on vaccination for at least one year in order to analyze
characteristics for long-term vaccination success. Factors
considered were disease type, intensity of prior che-
motherapy, tumor load and toxicity. Patients with AML
and high-risk MDS (n=25) as well as with ovarian (n=7),
thyroid (n=2), breast (n=1), gastric (n=1), and larynx
cancer (n=1), astrocytoma (n=1) and mesothelioma (n=4)
received 0.2mg HLA-A*0201-restricted WT1.126-134
peptide admixed with 1 mg KLH (day 3), and 62.5µg GM-
CSF (day 1-4) every 2 weeks x 4, followed by either
biweekly or monthly for 10 months and at increased inter-
vals of up to 3-monthly thereafter. Standard criteria were
used for response assessment. Patients remained on study
in absence of limiting toxicity and disease progression.
Toxicity to treatment was mild, and no patient went off
protocol for adverse events or consent withdrawal. Eleven
patients remained on study for more than 1 year with
disease control, including 3/19 patients with active AML,
4/9 patients with AML in CR, 2/7 patients with ovarian
cancer and 2/4 patients with mesothelioma. Of these
11 patients 4 remained on study for more than 3 years:
A 70 year old man with sAML from MDS, with 5%
marrow blasts at baseline and severe anemia after 3 cycles
of induction and consolidation chemotherapy, who was
58 months on study. A previously untreated woman with
AML with PD and 40% of marrow blasts at baseline, who
is 78+ months in SD on study, and a woman with AML in
CR after induction and consolidation therapy, who
achieved a second CR after initial relapse with 30%
marrow blasts during vaccination and 48+ months on
study. In addition a man with mesothelioma and PR after
initial pleurectomy, who is after 50+ months in SD still
being vaccinated. Overall, no correlation between prior
treatment and duration on vaccine was apparent, as 2/4
patients in long-term disease control had previously
aggressive chemotherapy. Of the solid tumor patients,
chemotherapy-pretreated ovarian cancer and mesothe-
lioma appear to be sensitive to WT1 vaccine, although
other histologies cannot be excluded due to low patient
numbers. These results further underline the potential of
WT1 targeting immunotherapies in cancer patients and
detailed immunological and molecular analyses might be
able to impact on improved vaccine design and to charac-
terize a certain subgroup of patients with specific benefit
from such therapies.
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